IPO - Inhibikase Therapeutics, Inc.

Form Type: S-3

Filing Date: 2025-06-20

Corporate Action: Ipo

Type: New

Accession Number: 000119312525143738

Filing Summary: Inhibikase Therapeutics, Inc. filed a Form S-3 registration statement with the SEC on June 20, 2025, to register a total of up to $300,000,000 in aggregate principal amount of various security types, including common stock, preferred stock, debt securities, warrants, and units. The registration includes a sales agreement prospectus supplement, allowing for the maximum offering of $200,000,000 of common stock through Jefferies LLC under an Open Market Sale Agreement. The common stock is quoted on the Nasdaq Capital Market under the ticker symbol 'IKT', with a closing price of $1.70 per share as of June 18, 2025. The funds are intended for general corporate purposes, encompassing working capital, capital expenditures, business development, and research and development. The document details the regulatory pathway for their lead product, IKT-001, intended for the treatment of pulmonary arterial hypertension (PAH), which includes discussions and approvals from the FDA regarding its development and market exclusivity prospects.